GX CN BIOTECH-U

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

China Biopharma spends 10 million HKD to repurchase 1.89 million shares on May 18

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

China Biopharma spends 10.0269 million HKD to repurchase 1.87 million shares

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Zhongtai Securities lowers Sanhome's earnings forecast and maintains Buy rating

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

China Biopharmaceutical Announces Preclinical Results of Obesity Treatment Candidate TQF6422

Hanson Pharma Group Begins HS-10541 Clinical Trial with NMPA Approval

China Bio-Pharmaceuticals repurchased 1.78 million shares

Innovent Biologics to Present Phase 3 Trial Results of Mazdutide at 2026 ADA Scientific Sessions

Sichuan Kelun Biotech Obtains Approval to Begin Clinical Trials for PD-1xVEGF Bispecific Antibody SKB118

CStone Pharmaceuticals Reaps Significant Benefits from 707 Authorization Deal with Pfizer

Jiangsu Hengrui Medicine Signs $950 Million Global R&D Agreement with Bristol-Myers Squibb

Hengrui Medicine and Braveheart Bio Report Positive Phase 2 Results for HRS/BHB-1893 in Treating nHCM

NTES-S

KWAN YONG

PEIJIA-B

REMEGEN

RADIANCE HLDGS

POP MART

BAOZUN-W

ARCHOSAUR GAMES

XIAOCAIYUAN

HEPALINK

159992

03174

09820

<p>ALPHAMAB-B (9966.HK) has seen a continuous decline after the market closed on January 20, with the overall Hong Kong biotechnology sector lacking excitement. The company has not announced any significant clinical progress or financing recently, and although trading volume slightly increased throughout the day, there was no significant action from major players, as investors' focus has shifted back to sector rotation. There are rumors in the news that the adjustment window for the medical insurance catalog is approaching, and market funds are leaning towards innovative drugs and emerging sectors, while ALPHAMAB has not shown significant movement following the hot trends. The intraday fluctuations have been mild, with no significant gathering of major players, and the buying pressure remains to be validated. On the technical side, the MACD continues to trend downward, and the 5-day moving average is providing short-term resistance, raising doubts about the sustainability of any rebound. Moving forward, attention should be paid to the substantive progress of medical insurance negotiations and the future structural rotation of the sector. If the biotechnology sector experiences another overall pullback or if the company faces unexpected negative news, short-term pressure may significantly increase. The operational suggestion is to continue observing from the right side, closely track marginal policy changes and sector movements, and wait for signals of major capital action to emerge</p>

Technical Forecast

Yinhua CSI Innovative Drugs Industry ETF

CSOP HEALTHCARE

Hwabao WP CSI Hong Kong Connect Medical Treatment Thematic ETF

Yinhua CSI HK Equities Medical and Health Integration ETF

GX CN BIOTECH

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund Hang Seng SCHK Innovative Drug ETF

CAM HSBIOTECH-U

Ping An CSI HK Equities Medical and Health Integration ETF

E Fund CSI HK Equities Medical and Health Integration ETF

Tianhong Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drugs Selected 50 ETF

Penghua CSI HK Connect Health Care Composite ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

CAM HSBIOTECH

Bosera Hang Seng SCHK Innovative Drug Select ETF

ALPHAMAB-B

Morning Trend | ALPHAMAB is testing the bottom with reduced volume, will the main opportunities in the pharmaceutical sector rotate?

GX CN BIOTECH-U(09820.HK)

Morning Trend | ALPHAMAB is testing the bottom with reduced volume, will the main opportunities in the pharmaceutical sector rotate?